Breast Cancer Update

Dr. Neil Love

Breast Cancer

Antibody-Drug Conjugates

Clinical Trials

Metastatic Breast Cancer

Triple Negative Breast Cancer

Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

Her2-Positive Breast Cancer

ESR1 Mutations

Chemotherapy

Quality Of Life

Er-Positive Metastatic Breast Cancer

TDXD

Endocrine Therapy

CDK4/6 Inhibitors

Cdk4-6 Inhibitors

Her2-Low Breast Cancer

Hormone Receptor-Positive Breast Cancer

Selective Estrogen Receptor Degraders

HER2 Positive Breast Cancer

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

95 ratings

Publishes	Weekly	Episodes	499	Founded	20 years ago
Number of Listeners		Categories	ScienceHealth & FitnessMedicine

Listen to this Podcast

Guests Host Reviews Charts Talking Points

Latest Episodes

For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)

• Current Clinical Role of Oral Selective Estrogen Rece... more

18 Aug 2026 • 1 hr 27 min

YouTube

For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

• Introduction (00:00)

• Identification of Appropriate Candidates for Agents Targeting the PI3K... more

10 Aug 2026 • 1 hr 29 min • Most popular

YouTube

For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)

• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) ... more

29 Jul 2026 • 1 hr 29 min

YouTube

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

• Introduction (0:00)

• Current and Future Roles of Agents Targ... more

25 Jul 2026 • 1 hr 58 min • Popular

Key Facts

Accepts Guests

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc DocsSam and Karine

Gastrointestinal Cancer UpdateDr. Neil Love

Oncology Today with Dr Neil LoveDr. Neil Love

Lung Cancer UpdateDr. Neil Love

Research To Practice | Oncology VideosDr Neil Love

Recent Guests

Reva Basho

Oncologist discussing PI3K pathway and mutations

Los Angeles, CA, United States

Episode: For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Kelly Fischer

Clinician sharing practical management and patient counseling

Boston, MA, United States

Episode: For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Melissa Rikal

Nurse practitioner discussing toxicity management and patient education

Nashville, TN, United States

Episode: For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Nick Turner

Physician-scientist presenting on PI3K pathway inhibitors and first-line strategies

Royal Marsden

Episode: Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Joyce O'Shaughnessy

Oncologist discussing ESR1 mutations and ESR1-directed SERDs

Texas Oncology, Sarah Cannon Research Institute

Episode: Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Erica Mayer

Oncologist discussing combination CERD strategies and AVERA-era data

Dana-Farber Cancer Institute

Episode: Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Sara Hurvitz

Oncologist discussing ESR1 mutations and ESR1-directed SERDs data

Fred Hutch/University of Washington

Episode: Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Sibylle Loibl

Professor, German Breast Group and Goethe University Frankfurt

German Breast Group; Goethe University Frankfurt

Episode: HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Hal Burstein

Dr. Hal Burstein, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Episode: Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Host

Neil Love

Host of the program; Research To Practice affiliation appears across episodes; frequently moderates expert discussions and case-based sessions.

Reviews

4.5 out of 5 stars from 95 ratings

Misc
Overall wonderful updates. Listen to these while driving. Would however appreciate if the Oncology nursing series was on a separate platform or podcasts. When one is driving the podcasts roll on and I don’t want to hear the nursing discussions .It is somewhat dangerous to be messing with the podcasts while driving. (With all due respect to nursing collegues). Also in areas where there is no reception, manually skipping a talk often just causes the connection to drop.
Apple Podcasts
5
worldhobo
United States5 years ago
Hem/onc fellow
I’m very grateful for these podcasts and educational videos and definitely owe majority of my hem/onc knowledge to Dr. Love! Looking forward to many more episodes across different disease sites!
Apple Podcasts
5
hem/onc fellow
United States7 years ago
Hemonc fellow
Outstanding discussions! I especially like the fact they those are patient centered and touch upon some ethical/personal dilemmas! I really hope to hear annual update, thank you Dr. Love!
Apple Podcasts
5
kdarbin
United States7 years ago
Hem/Onc fellow
Because of this podcast my knowledge in this field has grown substantially. It has helped me to keep up with the new data to deliver the best care to my patients. Thank you Dr. Love
Apple Podcasts
5
John.KH
United States7 years ago
The best
Simply one of the best most complete and informative podcasts in any medical topic ever made. I am a pediatrician and do not treat cancer. Yet I listen to every new episode. Outstanding.
Apple Podcasts
5
Bob a la sob mob
United States7 years ago

Embed These Reviews on a Website

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Listeners value practical clinical insights and case-based discussions.

Guests and host are praised for translating complex trial data into actionable guidance.

Some feedback suggests separating nursing-focused content onto a different platform, but overall reception is highly positive among clinicians.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts	#69	Ireland/Science
Apple Podcasts	#183	Israel/Science

Talking Points

Recent interactions between the hosts and their guests.

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Q: How long should maintenance continue after six cycles of T-DXd, and is there randomized data to guide stopping points?

Maintenance decisions should be made with patients, as no randomized data clearly define stopping after six cycles; some centers consider continuing while tolerating, and future maintenance studies may guide a switch to other regimens, but current practice varies and centers tailor to patient tolerance and preferences.

HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Q: In what situations would you not use T-DXd in first-line therapy?

The main limiting factors are frailty, age-related considerations, and significant preexisting pulmonary disease; otherwise, many patients without severe comorbidities were included in trials, favoring broader use with careful monitoring.

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Q: What is your view on using gerodestrant in adjuvant settings if approved, and how would you sequence it with CDK4/6 inhibitors in higher-risk patients?

The consensus acknowledged gerodestrant's potential, particularly in intolerant patients or those needing long-term endocrine therapy alternatives, but emphasized that sequencing with CDK4/6 inhibitors would be tailored to risk level and tolerability, with a preference to defer until CDK4/6 inhibitors have been used in higher-risk patients unless data strongly support earlier use.

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Q: Would you use a CERD monotherapy or a CERD plus targeted agent in ESR1-mutant patients who progressed after CDK4-6 inhibitors?

Many panelists favored a CERD-containing combination in ESR1-mutant patients with prior CDK4/6 inhibitors to address cross-resistance, though some remained cautious about monotherapy in certain contexts; the discussion highlighted ebalance between efficacy and toxicity, and the potential sequencing of CERDs with mTOR/PI3K inhibitors.

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Q: What first-line treatment would you recommend for a 65-year-old woman with HR-positive HER2-low metastatic breast cancer who develops metastatic disease after AI therapy and has a PI3K mutation?

The panel favored a combination approach in many scenarios, often preferring triplets or CERD-containing regimens in endocrine-resistant settings, especially if there is a PI3K mutation; however, decisions were individualized based on mutation status, prior therapies, and tolerability, with some favoring triplets like fulvestrant plus CDK4/6 inhibitors with a PI3K inhibitor when feasible.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Breast Cancer Update

What is Breast Cancer Update about and what kind of topics does it cover?

A clinically focused series that translates cutting-edge breast cancer research into practical guidance for practicing oncologists, hematologists, and fellows. Episodes feature in-depth interviews with leading clinicians and researchers, case-based discussions, and real-world considerations around sequencing, biomarkers, and novel therapies (including SIRDs, PI3K/AKT inhibitors, ADCs, and ctDNA-guided decisions). The show repeatedly emphasizes how new data affect patient selection, treatment duration, and toxicity management, with a strong emphasis on multidisciplinary perspectives and real-world applicability that helps clinicians implement trial findings in routine care. A standout trait is the commitment to translating complex trial data... more

Where can I find podcast stats for Breast Cancer Update?

Rephonic provides a wide range of podcast stats for Breast Cancer Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Breast Cancer Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Breast Cancer Update get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Breast Cancer Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Breast Cancer Update?

Rephonic provides comprehensive predictive audience data for Breast Cancer Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Breast Cancer Update have?

To see how many followers or subscribers Breast Cancer Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Breast Cancer Update?

These podcasts share a similar audience with Breast Cancer Update:

1. Two Onc Docs
2. Gastrointestinal Cancer Update
3. Oncology Today with Dr Neil Love
4. Lung Cancer Update
5. Research To Practice | Oncology Videos

How many episodes of Breast Cancer Update are there?

Breast Cancer Update launched 20 years ago and published 499 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Breast Cancer Update?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Breast Cancer Update?

Rephonic pulls ratings and reviews for Breast Cancer Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Breast Cancer Update?

Rephonic provides full transcripts for episodes of Breast Cancer Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Breast Cancer Update?

Recent guests on Breast Cancer Update include:

1. Reva Basho
2. Kelly Fischer
3. Melissa Rikal
4. Nick Turner
5. Joyce O'Shaughnessy
6. Erica Mayer
7. Sara Hurvitz
8. Sibylle Loibl

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days